Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Gross Margin (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Gross Margin for 7 consecutive years, with 78.25% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 5547.0% to 78.25% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 83.29% through Dec 2025, down 1102.0% year-over-year, with the annual reading at 83.29% for FY2025, 23.0% up from the prior year.
  • Gross Margin for Q4 2025 was 78.25% at Akebia Therapeutics, down from 84.03% in the prior quarter.
  • The five-year high for Gross Margin was 133.72% in Q4 2024, with the low at 2333.76% in Q2 2022.
  • Average Gross Margin over 5 years is 146.64%, with a median of 67.3% recorded in 2021.
  • The sharpest move saw Gross Margin tumbled -233455bps in 2022, then skyrocketed 241908bps in 2023.
  • Over 5 years, Gross Margin stood at 865.42% in 2021, then rose by 21bps to 686.77% in 2022, then skyrocketed by 108bps to 57.17% in 2023, then skyrocketed by 134bps to 133.72% in 2024, then plummeted by -41bps to 78.25% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 78.25%, 84.03%, and 84.12% for Q4 2025, Q3 2025, and Q2 2025 respectively.